BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 19172322)

  • 1. Tumefactive demyelinating lesions: nine cases and a review of the literature.
    Xia L; Lin S; Wang ZC; Li SW; Xu L; Wu J; Hao SY; Gao CC
    Neurosurg Rev; 2009 Apr; 32(2):171-9; discussion 179. PubMed ID: 19172322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic contrast-enhanced T2*-weighted MR imaging of tumefactive demyelinating lesions.
    Cha S; Pierce S; Knopp EA; Johnson G; Yang C; Ton A; Litt AW; Zagzag D
    AJNR Am J Neuroradiol; 2001; 22(6):1109-16. PubMed ID: 11415906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kidney Transplant Recipient With Tumefactive Demyelinating Lesions: A Case Report and Literature Review.
    Mu L; Wang M; Cheng L; Liu P; Wang K
    Transplant Proc; 2023 Oct; 55(8):1906-1909. PubMed ID: 37541863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study.
    Altintas A; Petek B; Isik N; Terzi M; Bolukbasi F; Tavsanli M; Saip S; Boz C; Aydin T; Arici-Duz O; Ozer F; Siva A
    Mult Scler; 2012 Oct; 18(10):1448-53. PubMed ID: 22419670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric tumefactive demyelination: case series and review of the literature.
    McAdam LC; Blaser SI; Banwell BL
    Pediatr Neurol; 2002 Jan; 26(1):18-25. PubMed ID: 11814730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of Apparent Diffusion Coefficient Values and Conventional MRI Features in Differentiating Tumefactive Demyelinating Lesions From Primary Brain Neoplasms.
    Mabray MC; Cohen BA; Villanueva-Meyer JE; Valles FE; Barajas RF; Rubenstein JL; Cha S
    AJR Am J Roentgenol; 2015 Nov; 205(5):1075-85. PubMed ID: 26496556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroimaging and clinicopathological differences between tumefactive demyelinating lesions and sentinel lesions of primary central nervous system lymphoma.
    Sun C; Han J; Lin Y; Qi X; Li C; Liu J; Qiu F
    Front Immunol; 2022; 13():986473. PubMed ID: 36059526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumefactive demyelinating lesions of 15 patients: Clinico-radiological features, management and review of the literature.
    Sánchez P; Meca-Lallana V; Barbosa A; Manzanares R; Palmí I; Vivancos J
    J Neurol Sci; 2017 Oct; 381():32-38. PubMed ID: 28991707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proton MR spectroscopy of tumefactive demyelinating lesions.
    Saindane AM; Cha S; Law M; Xue X; Knopp EA; Zagzag D
    AJNR Am J Neuroradiol; 2002 Sep; 23(8):1378-86. PubMed ID: 12223381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Large demyelinating lesions: a neurosurgical perspective.
    Salunke P; Aggarwal A; Gupta K; Agrawal P; Ahuja CK; Vasishta RK
    Br J Neurosurg; 2012 Aug; 26(4):490-8. PubMed ID: 22404734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumefactive demyelinating lesions.
    Dagher AP; Smirniotopoulos J
    Neuroradiology; 1996 Aug; 38(6):560-5. PubMed ID: 8880719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of tumefactive demyelinating lesions using MR imaging and in-vivo proton MR spectroscopy.
    Malhotra HS; Jain KK; Agarwal A; Singh MK; Yadav SK; Husain M; Krishnani N; Gupta RK
    Mult Scler; 2009 Feb; 15(2):193-203. PubMed ID: 19181773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent tumefactive demyelination in a child.
    Puri V; Chaudhry N; Gulati P; Tatke M; Singh D
    J Clin Neurosci; 2005 May; 12(4):495-500. PubMed ID: 15925795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mass lesions in the brain: tumor or multiple sclerosis? Clinical and imaging characteristics and course from a single reference center.
    Kilic AK; Kurne AT; Oguz KK; Soylemezoglu F; Karabudak R
    Turk Neurosurg; 2013; 23(6):728-35. PubMed ID: 24310455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and imaging correlation in patients with pathologically confirmed tumefactive demyelinating lesions.
    Tremblay MA; Villanueva-Meyer JE; Cha S; Tihan T; Gelfand JM
    J Neurol Sci; 2017 Oct; 381():83-87. PubMed ID: 28991721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monophasic, solitary tumefactive demyelinating lesion: neuroimaging features and neuropathological diagnosis.
    Tan HM; Chan LL; Chuah KL; Goh NS; Tang KK
    Br J Radiol; 2004 Feb; 77(914):153-6. PubMed ID: 15010391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of pediatric tumefactive demyelinating lesion misdiagnosed and treated as glioblastoma.
    Riva D; Chiapparini L; Pollo B; Balestrini MR; Massimino M; Milani N
    J Child Neurol; 2008 Aug; 23(8):944-7. PubMed ID: 18344459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumefactive demyelination: clinical, imaging and follow-up observations in thirty-nine patients.
    Nagappa M; Taly AB; Sinha S; Bharath RD; Mahadevan A; Bindu PS; Saini JS; Prasad C; Shankar SK
    Acta Neurol Scand; 2013 Jul; 128(1):39-47. PubMed ID: 23277913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinguishing tumefactive demyelinating lesions from glioma or central nervous system lymphoma: added value of unenhanced CT compared with conventional contrast-enhanced MR imaging.
    Kim DS; Na DG; Kim KH; Kim JH; Kim E; Yun BL; Chang KH
    Radiology; 2009 May; 251(2):467-75. PubMed ID: 19261924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study.
    Siri A; Carra-Dalliere C; Ayrignac X; Pelletier J; Audoin B; Pittion-Vouyovitch S; Debouverie M; Lionnet C; Viala F; Sablot D; Brassat D; Ouallet JC; Ruet A; Brochet B; Taillandier L; Bauchet L; Derache N; Defer G; Cabre P; de Seze J; Lebrun Frenay C; Cohen M; Labauge P
    J Neurol; 2015 Jul; 262(7):1637-45. PubMed ID: 25929666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.